Overview
- Shares fell 26.8% to $8.35 in premarket trading after the company lowered its fiscal 2027 revenue forecast to $510 million to $520 million from $545 million to $559 million.
- Management cited weaker visibility into drugmakers’ marketing budgets and smaller second‑half commitments tied to regulatory timing, including most favored nation pricing talks.
- Phreesia kept its adjusted EBITDA target at $125 million to $135 million as it leans on operating leverage and more AI tools to replace manual and outsourced work.
- The company now plans for mid‑single‑digit growth in its average number of healthcare service clients and only low‑single‑digit gains in revenue per client.
- Quarterly results released this week showed revenue of $127.07 million that topped forecasts and GAAP earnings of 2 cents per share, with adjusted earnings of 12 cents per share.